Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world

P. Vodicka, K. Benesova, A. Janikova, V. Prochazka, D. Belada, H. Mocikova, K. Steinerova, J. Duras, J. Karban, V. Hanackova, A. Sykorova, A. Obr, M. Trneny

. 2022 ; 109 (2) : 162-165. [pub] 20220511

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22025012

OBJECTIVES: Polatuzumab vedotin with bendamustine and rituximab (Pola-BR) was approved for treatment of transplant-ineligible patients with relapsed/refractory DLBCL (R/R DLBCL). However, the number of patients treated in the GO29365 trial including the extension cohort was limited, and more data evaluating the efficacy of this treatment regimen is needed. METHODS: We analyzed 21 patients with R/R DLBCL to determine real-life efficacy and safety of Pola-BR regimen. Data of all patients entered the database of the NiHiL project (NCT03199066). RESULTS: Median overall survival was 8.7 months, and progression-free survival 3.8 months. The overall response rate was 33%. Grade 3-4 neutropenia was detected in 29%, thrombocytopenia in 38%, anemia in 19%, infections in 24% cases, and peripheral neuropathy in 5%. Discontinuation of treatment was caused by progression in 50%, adverse events in 31%, and intended bridging to CAR-T therapy in 19%. CONCLUSION: Although the outcome of patients is worse than in GO29365 trial, the use of Pola-BR regimen in the real world demonstrates tolerable toxicity profile and efficacy in transplant-ineligible patients with R/R DLBCL. Moreover, this regimen might represent a perspective option as a bridge to CAR-T therapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22025012
003      
CZ-PrNML
005      
20221031100215.0
007      
ta
008      
221017s2022 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/ejh.13784 $2 doi
035    __
$a (PubMed)35502609
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Vodicka, Prokop $u First Department of Medicine, Charles University and General University Hospital, Prague, Czech Republic
245    10
$a Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world / $c P. Vodicka, K. Benesova, A. Janikova, V. Prochazka, D. Belada, H. Mocikova, K. Steinerova, J. Duras, J. Karban, V. Hanackova, A. Sykorova, A. Obr, M. Trneny
520    9_
$a OBJECTIVES: Polatuzumab vedotin with bendamustine and rituximab (Pola-BR) was approved for treatment of transplant-ineligible patients with relapsed/refractory DLBCL (R/R DLBCL). However, the number of patients treated in the GO29365 trial including the extension cohort was limited, and more data evaluating the efficacy of this treatment regimen is needed. METHODS: We analyzed 21 patients with R/R DLBCL to determine real-life efficacy and safety of Pola-BR regimen. Data of all patients entered the database of the NiHiL project (NCT03199066). RESULTS: Median overall survival was 8.7 months, and progression-free survival 3.8 months. The overall response rate was 33%. Grade 3-4 neutropenia was detected in 29%, thrombocytopenia in 38%, anemia in 19%, infections in 24% cases, and peripheral neuropathy in 5%. Discontinuation of treatment was caused by progression in 50%, adverse events in 31%, and intended bridging to CAR-T therapy in 19%. CONCLUSION: Although the outcome of patients is worse than in GO29365 trial, the use of Pola-BR regimen in the real world demonstrates tolerable toxicity profile and efficacy in transplant-ineligible patients with R/R DLBCL. Moreover, this regimen might represent a perspective option as a bridge to CAR-T therapy.
650    _2
$a monoklonální protilátky $7 D000911
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $7 D000971
650    _2
$a bendamustin hydrochlorid $7 D000069461
650    _2
$a lidé $7 D006801
650    12
$a imunokonjugáty $7 D018796
650    12
$a difúzní velkobuněčný B-lymfom $x diagnóza $x farmakoterapie $7 D016403
650    12
$a nehodgkinský lymfom $x farmakoterapie $7 D008228
650    12
$a chimerické antigenní receptory $7 D000076962
650    _2
$a rituximab $7 D000069283
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
700    1_
$a Benesova, Katerina $u First Department of Medicine, Charles University and General University Hospital, Prague, Czech Republic
700    1_
$a Janikova, Andrea $u Department of Hematology and Oncology, Faculty of Medicine, Masaryk University and University Hospital, Brno, Czech Republic
700    1_
$a Prochazka, Vit $u Department of Haemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
700    1_
$a Belada, David $u 4th Department of Internal Medicine - Hematology, Faculty of Medicine, Charles University and University Hospital, Hradec Kralove, Czech Republic
700    1_
$a Mocikova, Heidi $u Department of Internal Medicine - Hematology, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Steinerova, Katerina $u Department of Haemato-Oncology, Faculty of Medicine, Charles University and University Hospital Pilsen, Pilsen, Czech Republic
700    1_
$a Duras, Juraj $u Department of Hematology, Medical Faculty of the Ostrava University and University Hospital, Ostrava, Czech Republic
700    1_
$a Karban, Josef $u First Department of Medicine, Charles University and General University Hospital, Prague, Czech Republic
700    1_
$a Hanackova, Veronika $u Department of Haemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
700    1_
$a Sykorova, Alice $u 4th Department of Internal Medicine - Hematology, Faculty of Medicine, Charles University and University Hospital, Hradec Kralove, Czech Republic
700    1_
$a Obr, Ales $u Department of Haemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
700    1_
$a Trneny, Marek $u First Department of Medicine, Charles University and General University Hospital, Prague, Czech Republic
773    0_
$w MED00001620 $t European journal of haematology $x 1600-0609 $g Roč. 109, č. 2 (2022), s. 162-165
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35502609 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031100213 $b ABA008
999    __
$a ok $b bmc $g 1854622 $s 1176302
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 109 $c 2 $d 162-165 $e 20220511 $i 1600-0609 $m European journal of haematology $n Eur J Haematol $x MED00001620
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace